All
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi to sell 51% stake in Opella
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
By Dominique Patton PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
Sanofi Enters Exclusive Negotiations To Sell 50% Stake In Opella To CD&R
Sanofi (SNYNF) announced it has entered into exclusive negotiations to sell a 50 percent controlling stake in its consumer healthcare
Sanofi Sells Controlling Stake in Opella to CD&R with Job Guarantees
CD&R is nearing a deal to acquire control of Sanofi’s consumer health unit after it signed social commitments with the French government.
Sanofi Enters Exclusive Talks With CD&R Over Opella Stake Sale
Sanofi entered into exclusive talks to sell a controlling stake in its consumer-healthcare business Opella to Clayton Dubilier & Rice in a deal that values the business as a whole at 16 billion euros ($17.
Sanofi Enters Exclusive Talks to Sell 50% Stake in Opella to CD&R
Sanofis Exclusive Negotiations with Clayton Dubilier Rice Sanofi (NASDAQ: SNY) announced on Monday that it has entered exclusive negotiations to sell a 50% controlling stake in its consumer health division,
Sanofi, CD&R in Exclusive Negotiations for Sale, Purchase of 50% Stake in Opella
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
Sanofi enters exclusive talks with CD&R for Opella sale
Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.
1h
US takeover of prized French painkiller to go ahead
Sanofi announced on Monday that it had entered into exclusive negotiations with US investment fund CD&R to sell it a majority ...
1h
Sanofi pursues sale of painkiller after political controversy
Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after ...
5h
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcareSanofi and CD&R enter exclusive negotiations to transfer a 50% ...
56m
on MSN
France takes stake in Sanofi as it moves ahead with CD&R deal
US private equity firm CD&R has agreed to French government demands seeking to protect jobs and investment in France.
3m
Sanofi pursues sale of France's leading painkiller to US investment fund after controversy
French pharmaceutical company Sanofi confirmed on Monday its plans to sell a controlling stake in its consumer health unit ...
17h
CD&R Nears Sanofi OTC Deal After Signing With Government
Clayton Dubilier & Rice is nearing a deal to acquire control of Sanofi’s consumer health unit after the American buyout firm ...
PharmiWeb
2h
Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer ...
4d
on MSN
Sanofi in Talks With French Government to Address Concerns on Opella Deal
Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Sanofi
United States
France
Clayton
PAI Partners
Feedback